Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 5Terminated 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 81Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × ferumoxtran-10 × Clear all
NCT00659334 2022-12-21

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

OHSU Knight Cancer Institute

Phase 2 Terminated
116 enrolled 12 charts
CNS

Brain Neoplasms

NCT00147238 2012-08-07

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 3 charts
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡